Bottom line
BBH vs FBTAX: the short answer
BBH (VanEck Biotech ETF) and FBTAX (Fidelity Advisor Biotechnology Fund) are quite different portfolios: only about 35% of their top holdings (by weight) are shared.
But FBTAX is far broader, holding 129 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 0.94% — a difference of $59 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs +2.7% for BBH (reporting dates differ).
Updated Nov 19, 2026
BBH vs FBTAX side by side
| BBH | FBTAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | VanEck | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.94% |
| Annual cost per $10k | $35 | $94 |
| 10-yr cost on $10k (prospectus) | $443 | $1,663 |
| Max front load | None | — |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +21.2% | +31.5% |
| 5-yr return (annualized) | +2.7% | +6.4% |
| 10-yr return (annualized) | +4.5% | +7.7% |
| Best quarter | +27.6% | +30.3% |
| Worst quarter | −18.2% | −27.8% |
| Net assets (fund) | $395.6M | $2.2B |
| Number of holdings | 25 | 129 |
| Portfolio turnover | 19% | 54% |
| Returns as of | Dec 31, 2025 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | FBTAX | Difference |
|---|---|---|---|
| 2025 | +21.2% | +39.6% | −18.4% |
| 2024 | −4.4% | +5.3% | −9.7% |
| 2023 | +3.9% | +10.7% | −6.8% |
| 2022 | −15.1% | −8.0% | −7.2% |
| 2021 | +11.8% | −3.6% | +15.3% |
| 2020 | +22.1% | +32.2% | −10.1% |
| 2019 | +25.8% | +25.7% | +0.1% |
| 2018 | −10.2% | −3.8% | −6.4% |
| 2017 | +16.6% | +25.8% | −9.2% |
| 2016 | −15.0% | −23.6% | +8.5% |
Source: Fund prospectus bar charts
Holdings overlap
10 of BBH's top 25 holdings also appear in FBTAX's top 25.
| Holding | BBH | FBTAX |
|---|---|---|
| Amgen Inc | 15.25% | 2.37% |
| Gilead Sciences Inc | 12.79% | 5.70% |
| Vertex Pharmaceuticals Inc | 9.10% | 1.39% |
| Revolution Medicines Inc | 5.27% | 3.00% |
| Argenx SE | 4.97% | 3.00% |
| Natera Inc | 4.92% | 1.43% |
| Alnylam Pharmaceuticals Inc | 3.83% | 3.62% |
| Biogen Inc | 3.63% | 2.71% |
| Moderna Inc | 3.36% | 1.60% |
| Insmed Inc | 2.67% | 3.05% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
FAQ
What is the difference between BBH and FBTAX?
Which is cheaper, BBH or FBTAX?
Should I own both BBH and FBTAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.